Devil's Claw / Grapple Plant
Harpagophytum procumbens
Devil's Claw (Harpagophytum procumbens) from the Kalahari Desert is best known in European herbal medicine for arthritis and back pain, but emerging oncology research reveals interesting anti-cancer properties. Harpagoside and harpagide inhibit COX-2 and NF-κB — the same inflammatory pathways targeted by NSAIDs used in cancer prevention. Harpagoside specifically inhibits VEGF-induced angiogenesis and has shown anti-proliferative effects against colon, breast, and lung cancer cell lines. The San Bushmen of the Kalahari have long used the root for general debility, immune support, and cancer-like conditions. Its strongest validated use in cancer patients is for cancer-related pain and inflammatory conditions — well-supported by its anti-inflammatory mechanism.
Medicinal Properties
Cancer Types Studied
Recommended Dosage
50–100 mg harpagoside daily (standardised). Typical: 600–2400 mg dried root extract standardised to 2–3% harpagoside.
Preparations
Standardised Root Extract Capsules
600–1200 mg standardised Devil's Claw root extract (2–3% harpagoside) twice daily. Standardised to harpagoside content for consistent dosing.
Traditional Root Decoction
Simmer 1 tsp dried Devil's Claw root in 2 cups water for 15 minutes. Drink 1 cup twice daily on empty stomach. Used by San Bushmen for pain and debility.
NIH / PubMed Research
Links open on PubMed (National Library of Medicine). Research is ongoing — results may not reflect clinical use.
Cautions & Interactions
- May interact with warfarin and other anticoagulants — INR monitoring recommended
- May lower blood sugar — caution in diabetics
- May interact with antihypertensives
- Avoid during pregnancy — may stimulate uterine contractions
- Peptic ulcer patients: Devil's Claw stimulates gastric acid — take with food
Related Herbs
Informational only. Not medical advice. Consult your healthcare provider before use.